Luke Sergott
Stock Analyst at Barclays
(2.28)
# 1,203
Out of 4,641 analysts
228
Total ratings
43.1%
Success rate
-3.2%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Maintains: Equal-Weight | $285 → $275 | $254.71 | +7.97% | 36 | Oct 23, 2024 | |
| WAT Waters | Maintains: Underweight | $300 → $330 | $331.38 | -0.42% | 15 | Oct 15, 2024 | |
| TMO Thermo Fisher | Maintains: Equal-Weight | $600 → $620 | $571.00 | +8.58% | 22 | Oct 15, 2024 | |
| ILMN Illumina | Maintains: Equal-Weight | $125 → $135 | $141.72 | -4.74% | 13 | Oct 15, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $275 → $260 | $226.63 | +14.72% | 18 | Oct 15, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $350 → $330 | $278.68 | +18.42% | 15 | Oct 15, 2024 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $21 → $20 | $18.22 | +9.77% | 6 | Oct 15, 2024 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $14 | $10.61 | +31.95% | 13 | Oct 15, 2024 | |
| A Agilent Technologies | Maintains: Underweight | $135 → $145 | $132.41 | +9.51% | 5 | Oct 15, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $24 → $21 | $14.76 | +42.28% | 7 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $125 → $140 | $117.98 | +18.66% | 6 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $210 | $185.47 | +13.23% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $15.52 | +9.54% | 16 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $55 | $41.25 | +33.33% | 15 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $28 | $23.51 | +19.12% | 19 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $47 → $63 | $59.46 | +5.95% | 16 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.70 | +17.99% | 4 | May 10, 2024 |
Danaher
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $285 → $275
Current: $254.71
Upside: +7.97%
Waters
Oct 15, 2024
Maintains: Underweight
Price Target: $300 → $330
Current: $331.38
Upside: -0.42%
Thermo Fisher
Oct 15, 2024
Maintains: Equal-Weight
Price Target: $600 → $620
Current: $571.00
Upside: +8.58%
Illumina
Oct 15, 2024
Maintains: Equal-Weight
Price Target: $125 → $135
Current: $141.72
Upside: -4.74%
IQVIA Holdings
Oct 15, 2024
Maintains: Overweight
Price Target: $275 → $260
Current: $226.63
Upside: +14.72%
ICON Public Limited Company
Oct 15, 2024
Maintains: Overweight
Price Target: $350 → $330
Current: $278.68
Upside: +18.42%
Fortrea Holdings
Oct 15, 2024
Maintains: Equal-Weight
Price Target: $21 → $20
Current: $18.22
Upside: +9.77%
Certara
Oct 15, 2024
Maintains: Equal-Weight
Price Target: $16 → $14
Current: $10.61
Upside: +31.95%
Agilent Technologies
Oct 15, 2024
Maintains: Underweight
Price Target: $135 → $145
Current: $132.41
Upside: +9.51%
10x Genomics
Oct 15, 2024
Maintains: Overweight
Price Target: $24 → $21
Current: $14.76
Upside: +42.28%
Oct 15, 2024
Upgrades: Overweight
Price Target: $125 → $140
Current: $117.98
Upside: +18.66%
Aug 8, 2024
Maintains: Equal-Weight
Price Target: $230 → $210
Current: $185.47
Upside: +13.23%
Aug 6, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $15.52
Upside: +9.54%
Aug 5, 2024
Maintains: Overweight
Price Target: $60 → $55
Current: $41.25
Upside: +33.33%
Jul 29, 2024
Maintains: Overweight
Price Target: $25 → $28
Current: $23.51
Upside: +19.12%
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $47 → $63
Current: $59.46
Upside: +5.95%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.70
Upside: +17.99%